) Cutaneous malignancies represent the most common type of cancer in the United States. Understanding the biological basis of such cancers, leading to the development of improved therapies, is a major ongoing goal of the Cutaneous Oncology Program, which includes 23 investigators representing 10 departments and three off-site members. The Program includes basic scientists and clinicians with a common interest in understanding the biology of cutaneous neoplasms. One of the major long-term goals of the Cutaneous Oncology Program is to link the clinical activities in malignant melanoma, cutaneous T-cell lymphoma, and non-melanoma skin cancers with laboratory-based efforts aimed at prevention, improved diagnosis, and treatment of these diseases. The program has access to two large databases of patients with malignant melanoma and cutaneous T-cell lymphoma to assist in the examination of novel molecular determinants of tumor progression. Currently funded research undertaken by program members includes: molecular basis of basal cell nevus syndrome and xeroderma pigmentosum; calcium and keratinocyte differentiation; proteases and progression of squamous cell carcinoma; and multi-step cutaneous carcinogenesis in transgenic mice. Current cancer prevention and control efforts focus on understanding the biology of melanoma in women and improving the diagnostic skills of primary care physicians in the realm of non-melanoma skin cancers.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
